Eli Lilly & CO Form 4 insider transactions

Eli Lilly's EVP & CIDO, Diogo Rau, acquired 4,432.32 shares of common stock at $1,044.67 per share under a pre-arranged 10b5-1 plan.

Eli Lilly's Executive Vice President and Chief Financial Officer, Lucas Montarce, acquired 1,365.47 shares of common stock, signaling strong insider confidence.

Eli Lilly's EVP & President of International, Patrik Jonsson, acquired over 4,800 shares of common stock at a price of $1,044.67 per share.

Eli Lilly's EVP & President of Manufacturing Operations, Edgardo Hernandez, has filed a Form 4 indicating a planned acquisition of 4,383.734 shares of common stock on February 9, 2026, at a price of $1,044.67 per share.

Eli Lilly's EVP, General Counsel & Secretary, Anat Hakim, acquired 8,277.919 shares of common stock at $1,044.67 per share, totaling approximately $8.6 million.

Eli Lilly's EVP, Chief People Officer Eric Dozier, acquired 3,512.294 shares of common stock at $1,044.67 per share under a pre-arranged 10b5-1 plan.

Eli Lilly's EVP & President of Card Met Hlth, Kenneth L. Custer, acquired 659.28 shares of common stock at $1,044.67 per share in a pre-planned transaction.

Eli Lilly & Co. EVP, President LLY Imm, Adrienne S Brown, acquired 1,196.308 shares of common stock in a pre-planned transaction.

Eli Lilly & Co. executive Ilya Yuffa reported the vesting of restricted stock units and subsequent tax-related share disposition.

Eli Lilly's EVP Daniel Skovronsky reported the exercise of 12,684 restricted stock units and the subsequent sale of 5,641.249 shares for tax withholding purposes.

Eli Lilly & Co. EVP Jacob Van Naarden exercised restricted stock units and sold a portion of the resulting shares to cover tax liabilities.

Eli Lilly & Co's President, Chair, and CEO, David A. Ricks, acquired common stock through restricted stock unit exercise and subsequently sold shares for tax withholding purposes.

Eli Lilly's EVP & CIDO, Diogo Rau, reported the vesting of 3,752 restricted stock units and a subsequent sale of shares to cover tax liabilities.

Eli Lilly's EVP & President, International, Patrik Jonsson, acquired shares through RSU vesting and subsequently sold a portion for tax obligations.

An Eli Lilly executive reported the acquisition of common stock from restricted stock units and a subsequent disposition for tax withholding purposes.

Eli Lilly's EVP, GC & Secretary, Anat Hakim, reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Eli Lilly's EVP, Chief People Officer Eric Dozier, reported the acquisition and subsequent tax-related disposal of company common stock.

Eli Lilly director Gabrielle Sulzberger elected to defer cash compensation into 4.762 shares of common stock, to be settled upon separation from service.

Eli Lilly & Co. Director Juan R. Luciano acquired 15.286 shares of common stock by deferring cash compensation, increasing his beneficial ownership to 16,756.656 shares.

Eli Lilly director J. Erik Fyrwald acquired 9.523 shares of common stock by deferring cash compensation into stock units.

Eli Lilly Director Ralph Alvarez acquired 11.924 shares of common stock by deferring cash compensation into stock units under the company's deferral plan.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., sold 309,842 shares of common stock for approximately $340 million through pre-arranged transactions.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 1,390 shares of common stock for approximately $1,085.01 per share.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 3,593 shares of common stock for approximately $1,085.035 per share under a pre-planned Rule 10b5-1 arrangement.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 2,629 shares of common stock for approximately $1,085.17 per share.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 240 shares of common stock for approximately $1,085 per share.

Eli Lilly director Gabrielle Sulzberger acquired 4.668 shares of common stock through a deferred compensation plan, increasing her beneficial ownership to 2,956.674 shares.

Eli Lilly & Co. Director Juan R. Luciano acquired 13.965 shares of common stock, deferring cash compensation into stock units.

Eli Lilly & Co. Director Mary Lynne Hedley acquired 9.336 shares of common stock, valued at $1,062.19 per share, as deferred compensation.

Eli Lilly Director J. Erik Fyrwald acquired 9.336 shares of common stock, deferring cash compensation into stock units under the company's Directors' Deferral Plan.